Department of Infectious and Tropical Diseases, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Medical and Infectious Diseases Intensive Care Unit, Assistance Publique-Hôpitaux de Paris, Bichat-Claude Bernard University Hospital, Paris, France; Infections Antimicrobials Modelling Evolution (IAME) UMR 1137, University of Paris, Paris, France.
Lancet Infect Dis. 2020 Jun;20(6):697-706. doi: 10.1016/S1473-3099(20)30200-0. Epub 2020 Mar 27.
On Dec 31, 2019, China reported a cluster of cases of pneumonia in people at Wuhan, Hubei Province. The responsible pathogen is a novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report the relevant features of the first cases in Europe of confirmed infection, named coronavirus disease 2019 (COVID-19), with the first patient diagnosed with the disease on Jan 24, 2020.
In this case series, we followed five patients admitted to Bichat-Claude Bernard University Hospital (Paris, France) and Pellegrin University Hospital (Bordeaux, France) and diagnosed with COVID-19 by semi-quantitative RT-PCR on nasopharyngeal swabs. We assessed patterns of clinical disease and viral load from different samples (nasopharyngeal and blood, urine, and stool samples), which were obtained once daily for 3 days from hospital admission, and once every 2 or 3 days until patient discharge. All samples were refrigerated and shipped to laboratories in the National Reference Center for Respiratory Viruses (The Institut Pasteur, Paris, and Hospices Civils de Lyon, Lyon, France), where RNA extraction, real-time RT-PCR, and virus isolation and titration procedures were done.
The patients were three men (aged 31 years, 48 years, and 80 years) and two women (aged 30 years and 46 years), all of Chinese origin, who had travelled to France from China around mid-January, 2020. Three different clinical evolutions are described: (1) two paucisymptomatic women diagnosed within a day of exhibiting symptoms, with high nasopharyngeal titres of SARS-CoV-2 within the first 24 h of the illness onset (5·2 and 7·4 log copies per 1000 cells, respectively) and viral RNA detection in stools; (2) a two-step disease progression in two young men, with a secondary worsening around 10 days after disease onset despite a decreasing viral load in nasopharyngeal samples; and (3) an 80-year-old man with a rapid evolution towards multiple organ failure and a persistent high viral load in lower and upper respiratory tract with systemic virus dissemination and virus detection in plasma. The 80-year-old patient died on day 14 of illness (Feb 14, 2020); all other patients had recovered and been discharged by Feb 19, 2020.
We illustrated three different clinical and biological types of evolution in five patients infected with SARS-CoV-2 with detailed and comprehensive viral sampling strategy. We believe that these findings will contribute to a better understanding of the natural history of the disease and will contribute to advances in the implementation of more efficient infection control strategies.
REACTing (Research & Action Emerging Infectious Diseases).
2019 年 12 月 31 日,中国报告了湖北省武汉市发生的一组肺炎病例。致病病原体是一种新型冠状病毒,命名为严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)。我们报告了欧洲首例确诊感染的相关特征,称为 2019 年冠状病毒病(COVID-19),首例患者于 2020 年 1 月 24 日确诊。
在本病例系列中,我们对五名入住法国比沙提耶-克劳德·伯纳德大学医院(巴黎)和波尔多佩雷贡大学医院(波尔多)并通过鼻咽拭子半定量 RT-PCR 确诊 COVID-19 的患者进行了随访。我们评估了不同样本(鼻咽和血液、尿液和粪便样本)中临床疾病和病毒载量的模式,这些样本从入院后每天采集一次,连续采集 3 天,然后每隔 2 或 3 天采集一次,直到患者出院。所有样本均冷藏并运送到法国国家呼吸道病毒参考中心(巴黎巴斯德研究所和里昂公立医院),在那里进行 RNA 提取、实时 RT-PCR 以及病毒分离和滴定程序。
这五名患者均为男性(年龄分别为 31 岁、48 岁和 80 岁)和两名女性(年龄分别为 30 岁和 46 岁),均为中国人,于 2020 年 1 月中旬从中国前往法国。描述了三种不同的临床演变:(1)两名症状较轻的女性在出现症状的一天内被诊断出,发病后 24 小时内鼻咽 SARS-CoV-2 高滴度(分别为 5.2 和 7.4log 拷贝/1000 个细胞),粪便中检测到病毒 RNA;(2)两名年轻男性的疾病呈两步进展,尽管鼻咽样本中的病毒载量下降,但在发病后 10 天左右病情再次恶化;(3)一名 80 岁男性病情迅速恶化,导致多器官衰竭,下呼吸道和上呼吸道持续高病毒载量,全身病毒播散,血浆中检测到病毒。80 岁的患者于发病第 14 天(2020 年 2 月 14 日)死亡;所有其他患者均已康复并于 2020 年 2 月 19 日出院。
我们通过详细和全面的病毒采样策略,说明了五名感染 SARS-CoV-2 的患者的三种不同的临床和生物学演变类型。我们相信这些发现将有助于更好地了解疾病的自然史,并有助于推进更有效的感染控制策略的实施。
REACTing(新兴传染病研究与行动)。